1505 O'Brien Drive
Tel: 1 (650) 271-9888
23 articles with Synthekine
Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics
Synthekine Inc. today announced the closing of a $100 million Series C financing led by The Column Group, with participation from both new and existing investors.
Synthekine Inc. , an engineered cytokine therapeutics company, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
Synthekine Announces Multiple Poster Presentations Showcasing Its Three Distinct Cytokine Engineering Platforms at American Association for Cancer Research (AACR) 2022 Annual Meeting
Synthekine Inc today announced five poster presentations based on research spanning each of its three distinct cytokine engineering platforms at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022 taking place in New Orleans, LA from April 8-13, 2022.
Synthekine Doses First Patient in Phase 1 Clinical Trial of IL-2 Partial Agonist, STK-012, for Treatment of Solid Tumors
Synthekine Inc. , an engineered cytokine therapeutics company, today announced the dosing of the first patient in a Phase 1a/1b clinical trial of its IL-2 partial agonist, STK-012.
Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System
Synthekine Inc. today announced the publication of preclinical data for its lead cell therapy program using the orthogonal IL-2 receptor/ligand system in Science Translational Medicine.
Synthekine Establishes Collaboration with Merck to Develop Therapeutic Candidates Using its Proprietary Surrogate Cytokine Agonist Platform
Synthekine Inc. today announced it has entered into a worldwide research collaboration and license agreement with Merck, known as MSD outside the United States and Canada.
Under the agreement, Merck can use Synthekine's surrogate cytokine agonist platform to discover, develop, and sell new cytokine-based treatments for up to two cytokine targets.
11/1/2021Yet another busy week for clinical trial news. Here’s a look.
Synthekine Advances IL-2 Partial Agonist, STK-012, into Clinical Investigation for Treatment of Solid Tumors
Synthekine Inc. today announced it is advancing its IL-2 partial agonist, STK-012, into clinical investigation following clearance of its investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA).
6/16/2021Each week more money pours into the biopharma world. Here's a peek at who's getting a taste of fresh funds this week.
Synthekine Announces $107.5 Million Oversubscribed Series B Financing to Support Lead Programs to Clinical Proof of Concept, Advance Preclinical Programs and Platform
Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has closed an oversubscribed $107.5 million Series B financing.
Synthekine and Bright Peak made announcements on their Series B rounds, while Hawthorne Effect and Owl Peak Labs also secured their funding. Let us take a look.
6/4/2021Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.
Synthekine Expands Board of Directors, Management Team and Scientific Advisory Board with New Key Appointments
Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has appointed Mardi Dier to its board of directors, Robin Knifsend as senior vice president of finance and operations and Antoni Ribas, M.D., Ph.D., to its scientific advisory board.
5/7/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Synthekine Inc., an engineered cytokine therapeutics company, today announced a new agreement with Stanford University to license cytokine partial agonist programs for IL-10, IL-12 and IL-22. These programs augment a growing pipeline of selective cytokine partial agonists at Synthekine that is maturing toward clinical development.
Synthekine Presents Data at AACR Annual Meeting 2021 Demonstrating Selective IL-2 Partial Agonist, STK-012, Promotes Anti-Tumor Response without Related Toxicities
Synthekine Inc., an engineered cytokine therapeutics company, announced preclinical data presented at the American Association of Cancer Research Annual Meeting 2021 demonstrating its alpha/beta selective IL-2 partial agonist, STK-012, induced potent anti-tumor activity while avoiding the toxicities that have hindered the development of IL-2 therapeutics, including vascular leak syndrome.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Synthekine Strengthens Leadership with Board of Directors Expansion and Scientific Advisory Board Formation
Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has appointed Pablo Cagnoni, M.D., to its board of directors. Dr. Cagnoni brings to Synthekine extensive leadership experience in the biotech industry and a successful track record of oncology drug development.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.